← Signal Board

Crinetics Pharmaceuticals financial statements

NASDAQ:CRNX · Nasdaq
$84.95+0.00%
2026-09-02 close

Crinetics Pharmaceuticals's published financial data is dated 2026-10-04. 2024 revenue was $1M. 2024 operating profit was −$339M.

Reported results

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 14.94
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
14.94
Beneish M-Score
-2.07

No statistical flag

Sloan accrual
-5.05%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

5/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score5/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -21749%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-5547.2% → -32613.5%, -27066.3%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-32,613.5%
Interest coverage
-8.4x
Return on equity (ROE)
-22.5%

Operating margin −5pp

Operating loss
Interest coverageBase -8.4x adverse case -8.4x
Return on equity (ROE)Base -22.5% adverse case -28.6%

Revenue −15%

Interest coverage risk
Interest coverageBase -8.4x adverse case -7.1x
Return on equity (ROE)Base -22.5% adverse case -24.8%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -8.4x adverse case -7.9x
Return on equity (ROE)Base -22.5% adverse case -28.8%

Interest coverage limit

Already below the limit by 36,506.3pp

Interest coverage limit at an operating margin of 3,892.8%

Interest expense coverage threshold

Crinetics Pharmaceuticals notifications

Quantus Signal · live data · not investment advice · Privacy Policy